Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Cara Therapeutics Company Profile (NASDAQ:CARA)

Consensus Ratings for Cara Therapeutics (NASDAQ:CARA) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.00 (68.62% upside)

Analysts' Ratings History for Cara Therapeutics (NASDAQ:CARA)
Show:
DateFirmActionRatingPrice TargetDetailsShare
2/27/2014Needham & Company LLCInitiated CoverageBuyViewTweet This Rating  Share This Rating on StockTwits
2/27/2014Needham & Company LLCInitiated CoverageBuy$27.00ViewTweet This Rating  Share This Rating on StockTwits
2/25/2014Stifel NicolausInitiated CoverageBuy$21.00ViewTweet This Rating  Share This Rating on StockTwits
2/25/2014Canaccord GenuityInitiated CoverageBuy -> Buy$25.00ViewTweet This Rating  Share This Rating on StockTwits
2/25/2014Janney Montgomery ScottInitiated CoverageBuyViewTweet This Rating  Share This Rating on StockTwits
2/25/2014Piper JaffrayInitiated CoverageOverweight$23.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 4/17/2012 forward)